{"generic":"Influenza Virus Vaccine Recombinant","drugs":["Flublok","Influenza Virus Vaccine Recombinant"],"mono":{"0":{"id":"jxw4s0","title":"Generic Names","mono":"Influenza Virus Vaccine Recombinant"},"1":{"id":"jxw4s1","title":"Dosing and Indications","sub":{"0":{"id":"jxw4s1b4","title":"Adult Dosing","mono":"<b>Influenza; Prophylaxis:<\/b> 1 dose (0.5 mL) IM once annually "},"1":{"id":"jxw4s1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},"3":{"id":"jxw4s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Influenza; Prophylaxis<br\/>"}}},"3":{"id":"jxw4s3","title":"Contraindications\/Warnings","sub":[{"id":"jxw4s3b9","title":"Contraindications","mono":"severe allergic reactions (eg, anaphylaxis) to any vaccine component <br\/>"},{"id":"jxw4s3b10","title":"Precautions","mono":"<ul><li>Guillain-Barr  syndrome within 6 weeks of a previously administered influenza vaccine; evaluate benefit\/risk before administration<\/li><li>immunocompromised patients, including those receiving immunosuppressive therapy; immune response may be decreased<\/li><li>report adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http:\/\/www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jxw4s3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jxw4s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jxw4s4","title":"Drug Interactions","sub":{"1":{"id":"jxw4s4b14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Warfarin (probable)<\/li><\/ul>"},"2":{"id":"jxw4s4b15","title":"Moderate","mono":"<ul>Carbamazepine (probable)<\/ul>"}}},"5":{"id":"jxw4s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (19% to 37%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (8% to 11%)<\/li><li><b>Neurologic:<\/b>Headache (10% to 15%)<\/li><li><b>Other:<\/b>Fatigue (13% to 15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Pleuropericarditis, acute<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><\/ul>"},"6":{"id":"jxw4s6","title":"Drug Name Info","sub":{"0":{"id":"jxw4s6b17","title":"US Trade Names","mono":"Flublok<br\/>"},"2":{"id":"jxw4s6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jxw4s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxw4s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxw4s7","title":"Mechanism Of Action","mono":"The influenza virus vaccine recombinant contains recombinant hemagglutinin (HA) proteins of 3 influenza virus strains that are considered likely to be circulating in the United States during the influenza season for which the vaccine has been standardized. The HA proteins function as antigens to induce a humoral immune response.<br\/>"},"9":{"id":"jxw4s9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IM injection only<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake vial gently before use<\/li><li>administer IM, preferably in the deltoid muscle<\/li><li>do not mix with any other vaccine in the same syringe or vial<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jxw4s10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"11":{"id":"jxw4s11","title":"How Supplied","mono":"<b>Flublok 2014-2015 Formula<\/b><br\/>Intramuscular Solution: 135 MCG\/0.5 ML<br\/>"},"13":{"id":"jxw4s13","title":"Clinical Teaching","mono":"Drug may cause injection site pain, redness or swelling, headache, fatigue, and myalgia. <br\/>"}}}